AX-2025-018923 · CJC-1295 with DAC · TFS lot TFS-{CAT}-9795

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.31	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.69	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — deamidated (+1 Da)	0.44	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	91.87	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	91.24	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	1.99	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.816	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	90.8	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.07	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.66	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.40	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.40	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	14.46	min	14.62 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.19	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	68,855	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	1.15	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 68,855, and skew follows the reported asymmetry factor of 1.19. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.44 % impurity against a 99.31 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	CJC-1295 with DAC — main peak	14.46	4,826,774	99.31	—
2	deamidated (+1 Da)	14.20	21,385	0.44	+0.984
3	mod-GRF (1-29) (−279 Da)	12.70	6,804	0.14	-279.235
4	hydrolysed maleimide (+18 Da)	13.84	2,916	0.06	+18.011
5	maleimide dimer	16.88	2,430	0.05	+3644.975
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.07
Counter-ion (acetate)	ion chromatography	4.66
Residual solvent + inorganic residue	estimated	0.40
Total peptide content	by difference	91.87
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.28	99.31	divergence +0.21 pp vs batch median
Total impurities (% area)	0.37	0.69
Largest single impurity (% area)	0.72	0.44
Water (%)	not stated	3.07
Counter-ion (%)	not stated	4.66
Peptide content (%w/w)	not stated	91.87
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 25 d) → laboratory (courier, cold pack, 11 d) → assay.
Assay date: 11 Feb 2025
Submitted to the index: 20 Feb 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

uncertainty_budget20 Feb 2025

99.31 % is normalised area, so it is silent on how much peptide is in the vial. Content and water are the numbers that answer that, and both are on this record. Purity is the good news; content is the actionable news.

buyer_sourced20 Feb 2025

Buyer-sourced through an ordinary retail order, so the supplier had no opportunity to select the vial. This is the provenance class the index weights and it is roughly 87 % of the dataset.

sec_monomer20 Feb 2025

Where the close neighbour is an aggregate rather than a related substance, size exclusion separates them trivially and reverse phase never will.

hilic_hana20 Feb 2025

Nothing on this record is flagged for resolution and nothing will be. The figure exists so the reader can weight the purity number, which is its only purpose.

Section 7

Related records

Same batch — lot TFS-{CAT}-9795 n=10

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-018917	TFS-{CAT}-9795	Janoshik	2025-Q1	99.11	3.09	90.3	Buyer-sourced	2	MARGINAL
AX-2025-018918	TFS-{CAT}-9795	PeptideMeter	2025-Q1	98.84	3.69	—	Buyer-sourced	2	MARGINAL
AX-2025-018919	TFS-{CAT}-9795	Janoshik	2025-Q1	98.93	4.07	90.8	Laboratory-retained	2	MARGINAL
AX-2025-018920	TFS-{CAT}-9795	VendorInvestigate	2025-Q1	99.00	2.86	—	Laboratory-retained	2	MARGINAL
AX-2025-018921	TFS-{CAT}-9795	PeptideMeter	2025-Q1	99.18	3.17	—	Buyer-sourced	2	MARGINAL
AX-2025-018922	TFS-{CAT}-9795	Janoshik	2025-Q1	99.06	2.46	89.8	Buyer-sourced	3	MARGINAL
AX-2025-018924	TFS-{CAT}-9795	Janoshik	2025-Q1	99.36	3.13	90.8	Buyer-sourced	2	MARGINAL
AX-2025-018925	TFS-{CAT}-9795	Medutest	2025-Q1	99.08	2.79	—	Buyer-sourced	2	MARGINAL
AX-2025-018926	TFS-{CAT}-9795	Nordanalyt	2025-Q1	98.95	3.32	107.1	Buyer-sourced	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent CJC-1295 with DAC records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041681	TFS	TFS-{CAT}-9675	PeptideMeter	2026-Q3	98.82	3.67	—	Buyer-sourced	0	PASS
AX-2026-041867	SinoPep	SNP-2607-C3886	Janoshik	2026-Q3	99.24	5.12	—	Laboratory-retained	1	FAIL
AX-2026-041682	TFS	TFS-{CAT}-9675	Nordanalyt	2026-Q3	98.94	3.24	—	Buyer-sourced	0	PASS
AX-2026-041683	TFS	TFS-{CAT}-9675	Medutest	2026-Q3	98.68	3.46	97.0	Buyer-sourced	0	PASS
AX-2026-043471	BCH	BCH-2607-H5235	Janoshik	2026-Q3	97.46	5.48	—	Buyer-sourced	1	FAIL
AX-2026-043477	BCH	BCH-2607-H5235	VendorInvestigate	2026-Q3	97.62	5.32	99.6	Buyer-sourced	1	MARGINAL
AX-2026-043470	BCH	BCH-2607-H5235	Janoshik	2026-Q3	97.76	6.11	99.3	Supplier-supplied	1	MARGINAL
AX-2026-043478	BCH	BCH-2607-H5235	PeptideMeter	2026-Q3	97.63	5.42	90.1	Buyer-sourced	1	MARGINAL

Other recent TFS records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041681	CJC-1295 with DAC	TFS-{CAT}-9675	PeptideMeter	2026-Q3	98.82	3.67	—	Buyer-sourced	0	PASS
AX-2026-041766	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.54	6.34	—	Buyer-sourced	1	MARGINAL
AX-2026-041682	CJC-1295 with DAC	TFS-{CAT}-9675	Nordanalyt	2026-Q3	98.94	3.24	—	Buyer-sourced	0	PASS
AX-2026-041683	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	98.68	3.46	97.0	Buyer-sourced	0	PASS
AX-2026-041765	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.79	6.01	—	Buyer-sourced	0	PASS
AX-2026-041680	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	99.18	2.85	100.4	Buyer-sourced	0	PASS
AX-2026-041691	Semaglutide	TFS-{CAT}-9744	Janoshik	2026-Q2	98.31	6.07	91.4	Buyer-sourced	0	PASS
AX-2026-041700	SS-31 (Elamipretide)	TFS-{CAT}-1142	Medutest	2026-Q2	99.75	2.27	96.3	Buyer-sourced	0	PASS